Maiwei Biotech announced that the company received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and the clinical trial application for 9MW5211 injection for primary biliary cholangitis was approved. Previously, its application for clinical trials for various indications such as inflammatory bowel disease had been approved. This drug is an innovative antibody independently developed by the company, which is expected to open a new chapter in the precise treatment of autoimmune diseases. However, drug development is susceptible to uncertainties, and investors need to be aware of risks.

Maiwei Biotech announced that the company received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and the clinical trial application for 9MW5211 injection for primary biliary cholangitis was approved. Previously, its application for clinical trials for various indications such as inflammatory bowel disease had been approved. This drug is an innovative antibody independently developed by the company, which is expected to open a new chapter in the precise treatment of autoimmune diseases. However, drug development is susceptible to uncertainties, and investors need to be aware of risks.